October 19, 2021, 3:00 PM -
Event Type: Webinars
Several new intravenous lipid emulsions (ILE) have been approved by the FDA for adults receiving parenteral nutrition, providing a source of calories and essential fatty acids when nutritional needs cannot be met via the enteral route. With new ILEs available, clinicians must understand key differences between ILEs, available evidence, and the impact new ILEs may have on patient outcomes. This webinar will compare and contrast the available ILEs in the US. A discussion of the results of a retrospective study completed at a large US academic medical center evaluating clinical outcomes of soy-oil based ILE compared to a multi-oil ILE will follow. The speakers will then discuss how data was used to effect formulary changes at their institution.
- Compare and contrast available intravenous lipid emulsions (ILE) in the US market.
- Discuss the evidence for use of new ILEs in clinical care with a focus on optimizing outcomes.
- Share recent data from a large institutional study which evaluated clinical outcomes during a switch from a soy oil based ILE to a multi-oil ILE.
- Discuss rationale, pathway, and key evidence for proposing/justifying conversion to new ILE within your institution.
Paul Wischmeyer, MD, EDIC, FASPEN, FCCM, Professor of Anesthesiology and Surgery; Associate Vice Chair for Clinical Research, Dept. of Anesthesiology; Physician Director, TPN/Nutrition Support Service, DUH, Duke University School of Medicine
Krista Haines, DO, MABMH, Assistant Professor of Surgery, Division of Trauma, Critical Care, and Acute Care Surgery; Medical Director of Ethics, Duke University Hospital; Chair of Ethics Committee, Duke University Hospital
Mark DeLegge, MD, Co-owner of Delegge Medical; Senior Medical Director – IQVIA; Professor of Medicine, Medical University of South Carolina
This webinar is free for all participants.
This webinar is non-accredited and sponsored by